Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective
Molecular Pharmaceutics · 02.09.2024 · 21 (9) · 4238-4258
DOI: 10.1021/acs.molpharmaceut.4c00665 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 19.08.2024. Verfasst von Simone Alidori und 2 weiteren Autor:innen. Beteiligte Einrichtung: Independent Researcher, Havertown, Pennsylvania 19083, United States. Hauptthemen laut MEDLINE: Delayed-Action Preparations. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Fonden.
Abstract (Originalsprache)
The increasing focus on patient centricity in the pharmaceutical industry over the past decade and the changing healthcare landscape, driven by factors such as increased access to information, social media, and evolving patient demands, has necessitated a shift toward greater connectivity and understanding of patients' unique treatment needs. One pharmaceutical technology that has supported these efforts is long acting injectables (LAIs), which lower the administration frequency for the patient's provided convenience, better compliance, and hence better therapeutical treatment for the patients. Furthermore, patients with conditions like the human immunodeficiency virus and schizophrenia have positively expressed the desire for less frequent dosing, such as that obtained through LAI formulations. In this work, a comprehensive analysis of marketed LAIs across therapeutic classes and technologies is conducted. The analysis demonstrated an increasing number of new LAIs being brought to the market, recently most as aqueous suspensions and one as a solution, but many other technology platforms were applied as well, in particular, polymeric microspheres and in situ forming gels. The analysis across the technologies provided an insight into to the physicochemical properties the compounds had per technology class as well as knowledge of the excipients typically used within the individual formulation technology. The principle behind the formulation technologies was discussed with respect to the release mechanism, manufacturing approaches, and the possibility of defining predictive in vitro release methods to obtain in vitro in vivo correlations with an industrial angle. The gaps in the field are still numerous, including better systematic formulation and manufacturing investigations to get a better understanding of potential innovations, but also development of new polymers could facilitate the development of additional compounds. The biggest and most important gaps, however, seem to be the development of predictive in vitro dissolution methods utilizing pharmacopoeia described equipment to enable their use for product development and later in the product cycle for quality-based purposes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Independent Researcher, Havertown, Pennsylvania 19083, United States.
- Gilead Sciences, 333 Lakeside Drive, Foster City, California 94403, United States.
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.
ORCID-Profile: René Holm
Förderung
- Novo Nordisk Fonden
Zitieren
APA
Alidori, S., Subramanian, R., & Holm, R. (2024). Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective. Molecular Pharmaceutics, 21(9), 4238-4258. https://doi.org/10.1021/acs.molpharmaceut.4c00665
Vancouver
Alidori S, Subramanian R, Holm R. Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective. Molecular Pharmaceutics. 2024;21(9):4238-4258. doi:10.1021/acs.molpharmaceut.4c00665
BibTeX
@article{Alidori2024,
author = {Alidori, Simone and Subramanian, Raju and Holm, René},
title = {Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {9},
pages = {4238--4258},
doi = {10.1021/acs.molpharmaceut.4c00665}
}
EUVIMED